Sirolimus: a therapeutic advance for dermatologic disease

Sirolimus, also known as rapamycin (SRL, Rapamune®), was approved in 1999 by the US Food and Drug Administration to prevent graft rejection in renal transplantation. As a member of the mammalian target of rapamycin (mTOR) inhibitor class, its potent immunosuppressant, anti-angiogenic and anti-prolif...

Full description

Saved in:
Bibliographic Details
Published in:Skin therapy letter 2014-07, Vol.19 (4), p.1-4
Main Authors: Peters, T, Traboulsi, D, Tibbles, L A, Mydlarski, P R
Format: Article
Language:English
Subjects:
Age Factors
Angiofibroma - drug therapy
Angiofibroma - pathology
Animals
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - pharmacology
Immunosuppressive Agents - therapeutic use
Mice
Sarcoma, Kaposi - drug therapy
Sarcoma, Kaposi - pathology
Sirolimus - adverse effects
Sirolimus - pharmacology
Sirolimus - therapeutic use
Skin Diseases - drug therapy
Skin Diseases - pathology
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sirolimus, also known as rapamycin (SRL, Rapamune®), was approved in 1999 by the US Food and Drug Administration to prevent graft rejection in renal transplantation. As a member of the mammalian target of rapamycin (mTOR) inhibitor class, its potent immunosuppressant, anti-angiogenic and anti-proliferative properties are well recognized. When compared to other immunosuppressants, SRL has a lower risk of renal, neurologic and lymphoproliferative complications. It has become a promising treatment modality for angiofibromas, Kaposi's sarcoma and other inflammatory and malignant disorders of the skin. With the recent discovery that mTOR inhibitors extend the lifespan of mice, sirolimus and other rapamycin analogs (rapalogs) are emerging as therapeutic targets for the treatment and prevention of age-related diseases.
ISSN:1201-5989